| Cat. No. |
Product Name |
Information |
| PC-42493 |
BAY 11-7085
IκB inhibitor
|
BAY 11-7085 is an inhibitor of the expression of ICAM-1, VCAM-1, and E-selectin in human endothelial cells (IC50=5-10 uM), acts by selectively inhibiting TNFα-induced phosphorylation of IκB-α without affecting the constitutive IκB-α phosphorylation. |
| PC-45134 |
Iguratimod
COX-2 inhibitor, MIF inhibitor
|
Iguratimod (TT-614) is an antirheumatic agent that acts as an inhibitor of COX-2 with IC50 of 20 μM, does not inhibit COX-1, also inhibits macrophage migration inhibitory factor (MIF) with IC50 of 6.81 uM. |
| PC-45545 |
Lipoic acid
|
Lipoic acidis a multifunction antioxidant that has growth promoting, anti-inflammatory, antioxidative, immunostimulatory, and hypocholesterolemic properties. |
| PC-22689 |
ZM600
HSCs activation inhibitor
|
ZM600 is a novel antihepatic fibrosis compound that shows significant inhibitory effect on the activation of hepatic stellate cells (HSCs), specifically inhibits the activation of NF-κB, PI-3K/AKT, and TGF-β/Smads signaling pathways. |
| PC-21657 |
CSB-0914
NF-κB inhibitor
|
CSB-0914 is a small molecule NF-κB inhibitor that stably binds to NF-κB-p50 subunit, exhibits significant efficacy in reducing basophil activation assay induced by FcεRI receptors with IC50 of 98.4 nM. |
| PC-21362 |
AE-848
NF-κB modualator
|
AE-848 is a small molecule modulator of NF-κB and PI3K/AKT/mTOR signaling pathways, shows potent in vitro and in vivo anti-myeloma activity. |
| PC-21026 |
AS2676293
RANKL inhibitor
|
AS2676293 (AS 2676293) is an orally active small-molecule receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, inhibits RANKL-induced osteoclastogenesis using RAW264 cells with IC50 of 0.19 uM. |
| PC-20991 |
EVP4593
nSOC inhibitor
|
EVP4593 (EVP-4593) is an inhibitor of PMA/PHA-induced NF-κB pathway activation with IC50 of 9 nM, inhibits storeoperated calcium (Ca2+) entry (SOC) pathway in huntington's disease (HD) neurons. |
| PC-45990 |
(R)-(-)-Ibuprofen
|
An enantiomer of Ibuprofen that is generally not considered a COX inhibitor and is instead thought to be involved in pathways of lipid metabolism as it is incorporated into triglycerides along with fatty acids. |
